Objective To investigate the effect of up-regulation of long-chain non-coding RNA GHET1 on the prognosis of liver transplantation patients with hepatocellular carcinoma, and to explore whether it can be used as a potential molecular target for the detection and treatment of liver transplantation for liver cancer. Methods Twenty samples of hepatocellular carcinoma and corresponding cancer adjacent tissues were collected. The samples of hepatocellular carcinoma from 106 patients who underwent orthotopic liver transplantation were collected. Theywere divided into recurrence group and non-recurrence group according to whether there was a recurrence of hepatic carcinoma. According to the expression of GHET1, they were divided into the high expression group and low expression group. Quantitative real-time PCR （qRT-PCR） was used to detect the expression of GHET1 in all tissues. The relationships between GHET1 expression, the clinicopathological features and prognosis of HCC were analyzed. Results Compared with the adjacent non-tumor tissues, the expression of GHET1 was increased in hepatocellular carcinoma（P ＜ 0.001）. The results of clinical pathology analysis showed that GHET1 expression was closely related with tumor capsule （P ＜ 0.001）， tumor diameter （P ＜ 0.01）， differentiation grade （P ＜ 0.01）， vascular invasion（P ＜ 0.01） and TNM stage（P ＜ 0.01），but not related to the patient's age， gender， cirrhosis， serum AFP levels， serum NLR values， tumor location and tumor number （P ＞ 0.05）. In 106 liver cancer patients who underwent liver transplantation, the expressions of GHET1 were significantly higher in the recurrence group compared to the non-recurrence group （P ＜ 0.001） and the low-expression group. The cumulative recurrence rate in the high-expression group was significantly higher （P ＜ 0.05）. The cumulative survival rate in the high-expression group was significantly lower （P ＜ 0.001）. The difference was statistically significant. Conclusion GHET1 overexpression is associated with clinicopathological feature and poor prognosis. This conclusion suggests that GHET1 may be involved in the occurrence and development of HCC, and it can be used as a prognostic marker and clinical target in liver cancer patients who undergo liver transplantation.

Objective To observe the role of the donor specific antibody（DSA） and human leukocyte antigen（HLA） antibody in pediatric liver transplantation. Methods The clinical data of liver transplantation cases in some children (aged below 18 years) that were performed between Sep 1 2016 and Dec 31 2016 in Tianjin First Central Hospital，were analyzed retrospectively. HLA antibodies were detected by Luminex before liver transplantation, 1 week after surgery and 3 months after surgery. HLA typing was detected in HLA antibody positive specimens. The incidences of rejection, cytomegalovirus （CMV） infection, EB virus infection, vascular complications and biliary complications after liver transplantation were observed. Results A total number of 11 cases were included. DSA was found positive in 1 case before liver transplantation, and in 1 case after liver transplantation. HLA antibodies of 2 cases were positive (non-DSA) before liver transplantation and negative after liver transplantation. The tests for HLA antibody of 1 case were positive before liver transplantation，one week and 3 months after operation. The HLA antibody in 1 case was positive 1 week after liver transplantation. HLA antibody in 5 cases was negative before and after liver transplantation. The average follow-up time of 11 patients was 15.3±1.9 months. All patientssurvived and no rejection was observed after liver transplantation. One case presented hepatic artery thrombosis on the third day and hepatobiliary anastomostic bile leakage occurred on the sixth day after liver transplantation. One case of anastomotic stenosis was found on the third day after liver transplantation. There were two cases of Cytomegalovirus infection and one case of EB virus infection after surgery. Conclusion Detection of DSA and HLA antibody in the early period of pediatric liver transplantation complications.has a certain significant

Objective To investigate the causes of coagulation dysfunction in orthotopic liver transplantation by observing the results of thrombelastography（TEG） heparinase test. Methods There were 24 cases of patients undergoing orthotopic liver transplantation, including 20 males and 4 females. The age of included patients was 41 ~ 60 years old， and weight was 48 ~ 86 kg. All cases received orthotopic liver transplantation without bypass. The total amount of red blood cells and plasma used in the operation were recorded. The central venous blood sample was collected at the 15th min in the new liver stage and tested by the TEG analyzer. The blood samples were added to the TEG heparinase test cup and TEG normal test cup. If the two kinds of TEG did not coincide and the difference was significant， the protamine was given， and then the TEG tests were repeated. Results All the patients received a stable operation. At the 15th min in the new liver stage， the R， K，αangle and MA in TEG heparinase test cup group were significant difference compared to the normal test cup group（P ＜ 0.05）. After the protamine was given, results of tests suggested that there was no significant difference between the TEG heparinase test cup group and TEG normal test cup group in R， K，αangle and MA（P ＞ 0.05） Conclusion The anticoagulant effect of heparin is th e main factor of early coagulation dysfunction in new liver stage.